Neurosense Therapeuti -CW23NRSNWPreferred / convertible
13F holders, Q2 2026 (June 30)3holders
0new positions
0sold out
$0.06avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Neurosense Therapeuti -CW23 (NRSNW) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Empery Asset Management, LP ($6K), Clear Street Group Inc. ($4K) and UBS Group AG ($73).
- Company
- Neurosense Therapeuti -CW23
- CUSIP
- M74240116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 300 shares sold, net −300 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Empery Asset Management, LP | — | No change | 100,402 | $6K |
| Clear Street Group Inc. | — | Reduce -0.5% | 63,085 | $4K |
| UBS Group AG | — | No change | 1,163 | $73 |
"% of holder's portfolio" is NRSNW's weight in each manager's 13F, not the share of Neurosense Therapeuti -CW23 the manager owns.